Vivek Subbiah: Another Tissue-Agnostic FDA approval
Vivek Subbiah shared on LinkedIn: .
“Yes! We have another Tissue-Agnostic FDA approval today! The 3rd NTRK (Neurotrophic Tyrosine Receptor Kinase) inhibitor !!!
FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors.
- ORR in the TKI-naïve group= 58%
- ORR in TKI-pretreated group = 50 % “
Read our latest paper about tissue-agnostic drug development in CA Journal for Clinicians – a journal with the highest impact factor in all of oncology American Cancer Society‘s flagship journal.”
Further details.
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.